ERBB2 and adenocarcinoma: Consequently, the gene silencing and/or drug‐dependent inhibition of the MR kinases AKT1, CDK1&2, ERBB2 and the downstream kinase EGFR markedly reduced cell viability in a large panel of human adenocarcinoma cell lines (Table S11).